CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 

Fibrogen Inc 's Quick Ratio

FGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 1.2 a new company low.

Within Major Pharmaceutical Preparations industry 353 other companies have achieved higher Quick Ratio than Fibrogen Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 966 to 1540.

Explain Quick Ratio?
How much Cash & cash equivalents FGEN´s has?
What are FGEN´s Current Liabilities?


FGEN Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -16.9 % -19.25 % -0.25 % 21.32 % 20.39 %
Y / Y Cash & cash equivalent Change -38.48 % -23.38 % -16.85 % 4.15 % -16.01 %
Quick Ratio MRQ 1.2 1.73 1.4 1.54 1.62
FGEN's Total Ranking # 1540 # 966 # 1181 # 600 # 1613
Seq. Current Liabilities Change 7.91 % -23.82 % -6.88 % 8.56 % 4.85 %
Seq. Cash & cash equivalent Change -25.13 % -5.68 % -15.65 % 3.3 % -6.76 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 354
Healthcare Sector # 656
Overall Market # 1540


Quick Ratio Statistics
High Average Low
10.66 4.6 1.2
(Sep 30 2017)   (Sep 30 2023)




Financial Statements
Fibrogen Inc 's Current Liabilities $ 209 Millions Visit FGEN's Balance sheet
Fibrogen Inc 's Cash & cash equivalent $ 251 Millions Visit FGEN's Balance sheet
Source of FGEN's Sales Visit FGEN's Sales by Geography


Cumulative Fibrogen Inc 's Quick Ratio

FGEN's Quick Ratio for the trailling 12 Months

FGEN Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -16.9 % -19.25 % -0.25 % 21.32 % 20.39 %
Y / Y Cash & cash equivalent TTM Growth -38.48 % -23.38 % -16.85 % 4.15 % -16.01 %
Quick Ratio TTM 1.46 1.56 1.59 1.66 1.73
Total Ranking TTM # 1280 # 3803 # 2672 # 1316 # 1188
Seq. Current Liabilities TTM Growth 7.91 % -23.82 % -6.88 % 8.56 % 4.85 %
Seq. Cash & cash equivalent TTM Growth -25.13 % -5.68 % -15.65 % 3.3 % -6.76 %


On the trailing twelve months basis In spite of the year on year decrease in FGEN's Current Liabilities to $209.42 millions, cumulative Quick Ratio to 1.46 below the FGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 371 other companies have achieved higher Quick Ratio than Fibrogen Inc . While Quick Ratio overall ranking has improved so far to 1280, from total ranking during the twelve months ending second quarter 2023 at 3803.

Explain Quick Ratio?
How much Cash & cash equivalents FGEN´s has?
What are FGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 372
Healthcare Sector # 673
Within the Market # 1280


trailing twelve months Quick Ratio Statistics
High Average Low
8.89 4.95 1.46
(Jun 30 2018)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Annovis Bio Inc   3.30 $ 6.355  Millions$ 1.926  Millions
Harmony Biosciences Holdings inc   3.30 $ 370.674  Millions$ 112.408  Millions
Xoma Corporation  3.24 $ 33.472  Millions$ 10.334  Millions
Zomedica Corp   3.23 $ 21.783  Millions$ 6.740  Millions
Gt Biopharma Inc   3.20 $ 16.014  Millions$ 4.998  Millions
Cue Biopharma Inc   3.18 $ 54.691  Millions$ 17.207  Millions
Eyenovia inc   3.16 $ 20.702  Millions$ 6.548  Millions
Ocular Therapeutix Inc   3.15 $ 110.550  Millions$ 35.066  Millions
Arvinas Inc   3.15 $ 998.500  Millions$ 317.300  Millions
Regeneron Pharmaceuticals Inc   3.12 $ 9,913.600  Millions$ 3,181.300  Millions
Hepion Pharmaceuticals inc   3.07 $ 19.284  Millions$ 6.290  Millions
Azitra Inc   3.03 $ 4.400  Millions$ 1.454  Millions
Nextcure Inc   2.98 $ 19.519  Millions$ 6.552  Millions
Gain Therapeutics Inc   2.93 $ 12.233  Millions$ 4.179  Millions
Corcept Therapeutics Inc  2.91 $ 355.225  Millions$ 121.873  Millions
Ainos Inc   2.89 $ 2.371  Millions$ 0.820  Millions
Avadel Pharmaceuticals Plc  2.88 $ 153.179  Millions$ 53.138  Millions
Cara Therapeutics inc   2.81 $ 62.875  Millions$ 22.384  Millions
G1 Therapeutics Inc   2.80 $ 94.352  Millions$ 33.653  Millions
Aptevo Therapeutics Inc   2.80 $ 19.110  Millions$ 6.836  Millions
Monopar Therapeutics Inc   2.78 $ 5.515  Millions$ 1.982  Millions
Arrowhead Pharmaceuticals Inc   2.78 $ 292.735  Millions$ 105.456  Millions
Clene Inc   2.76 $ 42.113  Millions$ 15.268  Millions
Mersana Therapeutics inc   2.74 $ 186.283  Millions$ 67.933  Millions
Neubase Therapeutics inc   2.73 $ 12.696  Millions$ 4.650  Millions
Genprex Inc   2.70 $ 11.711  Millions$ 4.338  Millions
Evoke Pharma Inc   2.68 $ 5.965  Millions$ 2.227  Millions
Hookipa Pharma inc   2.65 $ 107.676  Millions$ 40.576  Millions
Bellicum Pharmaceuticals Inc   2.63 $ 5.909  Millions$ 2.249  Millions
Kiora Pharmaceuticals Inc   2.59 $ 5.400  Millions$ 2.082  Millions

Date modified: 2023-11-07T13:07:54+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com